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Abstract  
 
Sulindac loaded poly(HEMA) cross-linked microparticles were synthesized via one-pot free-
radical dispersion polymerisation in supercritical carbon dioxide (scCO2) in presence of 
photocleavable diblock stabilisers based on polyethylene oxide (PEO) and 
poly(heptadecafluorodecyl acrylate) (PFDA) bearing a o-nitrobenzyl photosensitive junction 
(hv) (PEO-hv-PFDA), and ethylene glycol dimethacrylate (EGDMA) as cross-linker. Poly(HEMA) 
cross-linked microparticles either empty or sulindac loaded were obtained with well-defined 
spherical morphology with the sizes between 250-350 nm. Additionally, upon UV-photolysis 
the stabiliser on the surface was cleaved which permits to microparticles to be redispersed in 
water leading to water swollen microgels about 2.1-3.6 µm. Moreover, the release behaviour 
from obtained microgels indicated the sustained release of sulindac over 10 days. Besides, 
the surface modification after UV-photolysis was studied and proved that the particles can be 
functionalised with further chemistries. 
Keywords: 2-hydroxyethyl methacrylate, cross-linked particle, microgel, sulindac, supercritical 
carbon dioxide.  
1. Introduction  
 
There has been a tremendous growth in the field of designing controlled delivery systems 
based on polymer carriers, one of them being hydrogel formulations based on 
(sub)microparticles referred also as micro- or nanogels. These systems combine the 
characteristics of both hydrogels and particles being a 3D network able to swell in water/ 
biological fluids and at the same time having a small size and large surface area (Hamidi et al., 
2008). Unique features of these networks made them promising candidates to be used in 
biomedical fields such as tissue engineering, regenerative medicine, diagnostics and many 
more (Ryu et al., 2010). 
These hydrogel particles can be easily prepared using heterogeneous free radical 
polymerisation techniques such as dispersion, inverse mini or micro emulsion by introducing 
a suitable difunctional monomer as cross-linker to the reaction mixture (Chacko et al., 2012). 
In dispersion polymerisation by using a proper stabiliser the formed polymers can be 
dispersed in the continuous phase resulting into spherical particles with sizes ranging 
between 100 nm to 10 µm with narrow size-distribution (Cao et al., 2006). In recent years, an 
increasing interest was devoted to the use of supercritical carbon dioxide, i.e. a non-toxic and 
environmental friendly solvent as medium for heterogeneous processes to produce particles 
(Jennings et al., 2013). Supercritical carbon dioxide (scCO2) is a non-toxic, non-flammable, 
inexpensive and environmentally benign solvent with easily achievable critical point, i.e. 
Tc=31.1°C and Pc=73.8 bar. The aforementioned moderate critical points of CO2 allow 
processing conditions compatible with thermo- sensitive drugs. It is also an inert medium 
which prevents oxidation (Cocero et al., 2009). Moreover, upon depressurisation, CO2 goes 
to gaseous state which offers dry condition at low temperature enabling to handle water, 
solvent and heat labile substances (Davies et al., 2008). Moreover, since the CO2 can be 
removed from the media easily, energy consuming solvent removal stage is avoided which 
allows us to produce dry powder formulations (Miyazaki et al., 2017). Therefore, scCO2 has 
taken great attention in pharmaceutical applications as a solvent or anti-solvent to either 
extract or process bioactive agents, most importantly a medium for producing drug loaded 
polymer particles with enhanced bioavailability (Nuchuchua et al., 2017).  
Non-steroidal anti- inflammatory drugs (NSAID)s are frequently used for the treatment of 
acute and chronic inflammation and related pain. Therefore, they are prescribed in large 
quantities worldwide for the patients and their use is expected to rise in the future (Gerstein 
et al., 2014). For instance, aspirin, ibuprofen, diclofenac are some of the well-known and 
mostly used examples of NSAIDs. NSAIDs can be classified into different groups with respect 
to their chemical structure and sulindac falls into the indoleacetic acid group along with 
indometacin, tolmetin and ketorolac. We are specifically interested in sulindac since it was 
reported to have promising anti-proliferative activity towards different cancer types both in 
vitro and in vivo. For instance, sulindac was tested in cell lines of acute myeloid leukemia 
(AML) and primary cells from bone marrow of the patients (Singh et al., 2011). Moreover, it 
is also found to relieve the pain from arthritis such as osteoarthritis and rheumatoid (Lee et 
al., 2010). 
Even though in general NSAIDs are taken orally, they are either practically insoluble or 
sparingly soluble in aqueous environment; they have low bioavailability and show poor 
stability which results in storage problems. Also in long-term, they cause gastrointestinal side 
effects. Therefore to overcome these problems, studies are focused on encapsulation of the 
NSAIDs into polymeric carriers (Badri et al., 2016).  Ammar et al.  have prepared chitosan and 
carboxymethyl-β-cyclodextrin (CM-β-CD) cross-linked nanoparticles for the encapsulation of 
sulindac (Ammar et al., 2012). Carmona-Moran et al. have encapsulated diclofenac (NSAID) 
in poly(N-vinylcaprolactam)-co-acrylic acid core-shell nanogels and embedded in the solid 
hydrogel matrix for transdermal applications (Carmona-Moran et al., 2016). Choudhary et al. 
encapsulated sulindac in hydrophobically modified alginate gels. However, in the preparation 
of these nanogels, extensive purification time (i.e 4 weeks) is required before loading the drug 
by impregnation or diffusion (Choudhary et al., 2017).  In addition to these hydrogels, poly(2-
hydroxyethyl methacrylate) (poly(HEMA)) was also investigated previously by Andrade-Vivero 
et al. to be used for the delivery of diclofenac and ibuprofen (NSAID)s (Andrade-vivero et al., 
2007).  
2-hydroxyethyl methacrylate is a hydrophilic monomer and its homo- or copolymers find well-
established biomedical applications (Abraham et al., 2005; Cadotte and Demarse, 2005; 
González-Chomón et al., 2012). The poly(HEMA) hydrogels are widely used  to deliver drugs 
from drug-eluting implants (Long et al., 2014; Macková et al., 2017) in reconstructive 
materials in dental applications (Kitagawa et al., 2014), in ocular treatment (Garcia-Millan et 
al., 2015) and also to deliver proteins (Hackl et al., 2017).  
The aim of the present paper is to produce well-defined and submicronic poly(HEMA) 
particles encapsulating sulindac by dispersion polymerisation  in supercritical carbon dioxide. 
As already reported by Ma et al. (Ma and Lacroix-desmazes, 2004) polyethylene oxide (PEO) 
block poly(heptadecafluorodecyl acrylate) (PFDA) (PEO-b-PFDA) diblock copolymers are 
efficient stabilisers for the poly(HEMA) particles in supercritical carbon dioxide. In addition, 
some of us have also reported  mild conditions, especially low temperature (35°C)  for HEMA 
dispersion polymerisation in scCO2 giving well-defined and small sized particles (216 nm) 
(Parilti et al., 2017) (Scheme 1, step 1).  In addition, Alaimo et al. have shown that the use of 
a photocleavable junction between the polyethylene oxide (PEO) and 
poly(heptadecafluorodecyl acrylate) (PFDA) blocks of the stabiliser (PEO-hν-PFDA) allows to 
remove the fluorinated block after the particles synthesis and as a consequence allows the 
poly(HEMA) particles to swell in water (Scheme 1, step 2) (Alaimo et al., 2017).  
In the present paper, we have studied further such process targeting the one-pot 
encapsulation of sulindac, by adding the drug from the beginning of the process. Therefore, 
the effect of the presence of the drug on the particle size and overall particles properties has 
been evaluated. The drug encapsulation and release profile in aqueous media are also 
reported here.  
 
Scheme 1: Synthetic approach to obtain sulindac loaded poly(HEMA) hydrogels in supercritical carbon 
dioxide(scCO2) using photocleavable stabilisers.  
2. Experimental Part  
2.1 Materials  
All chemicals are purchased from Sigma-Aldrich and used as received unless otherwise it is 
noted. Sulindac (≥98.0%), fluoresceinamine, isomer I, sodium cyanoborohydride (1.0 M in 
THF), 2,2'-Azobis(4-methoxy-2,4-dimethylvaleronitrile) (V-70,Wako), 2-hydroxyethyl 
methacrylate (HEMA, Aldrich, 97%), ethylene glycol dimethacrylate (EGDMA, Aldrich, 98%,), 
carbon dioxide (I5122,CO2 N27 purity > 99,999%, Air Liquide, Belgium). α,α,α -
Trifluorotoluene (TFT, Aldrich, 99+%),. Ultrapure water was produced by MilliQ plus 188 
apparatus (Millipore). SpectraPor membrane (cut-off 3.5 kDa and 1kDa). PEO45-hν-PFDA50 
diblock copolymer bearing a photocleavable junction was synthesized according to previously 
published procedure.(Alaimo et al., 2017) 
2.2 Methods  
2.2.1 Synthesis of the sulindac encapsulated poly(HEMA) networks in scCO2  
Dispersion polymerisations of 2-hydroxyethyl methacrylate were performed as previously 
described by Parilti et al. (Parilti et al., 2017). The procedure can be described as follows: the 
high pressure stainless steel cell (82 ml, ToP Industrie) was charged with 8.2 ml of HEMA (10% 
v/v CO2), 400 µl of EGDMA (cross-linker, 5% v/v monomer), 0.82 g of stabiliser, 0.187 g V-70 
(1% w/v monomer) and 8.79 mg/ 87.9 mg sulindac (0.1% or 1% with respect to wHEMA). The 
cell was securely sealed and a small amount of CO2 was introduced using a syringe pump (ISCO 
model no. 260D). After the heating mantel was clamped, the stirring rate (400 rpm) and 
temperature (35°C) were set with the control unit. Temperature and pressure were increased 
step-wise, the reactor was stabilised at the desired conditions (35°C/300 bar) and the reaction 
was left for stirring overnight. At the end of the reaction, stirring was stopped and the heating 
jacket removed allowing the reactor to cool down to ambient temperature. Thereafter, the 
reactor is depressurized gradually by opening an outlet valve. After total depressurization, 
the cell was opened and the product was collected as a dry powder. Obtained products were 
stored in the ambient temperature in a plastic container. 
2.2.2 UV photolysis of the particles 
The particles were dispersed in TFT with the concentration of 10 mg/ml. The solution was 
sonicated using horn sonicator for about 3 minutes resulting into a milky dispersion. 
Thereafter solution was subjected to UV under vigorous stirring (700 rpm) using UV lamp 
(LOT-Oriel Arc Light Source Hg(Xe), power=500 W, with multichromatic emission showing the 
characteristic emission at 300-310 nm for the photocleavage of o-nitrobenzyl groups. The UV 
exposure times were varied from 30 minutes to 60 minutes.  
2.2.3 Release behavior 
After fluorine extraction, 50 mg of particles were placed into a dialysis membrane with a cut 
off of 100 kDa (SpectraPor® membrane) and 5 ml of Milli-Q water was then added 
(concentration 10 mg/ml). The membrane was placed in brown glass bottle with 100 ml of 
Milli-Q water (in sink conditions) and left for shaking in an orbital stirrer at 37°C at a speed of 
50 rpm. Samples (1ml) were taken from the external medium of the membrane in different 
time intervals, and 1 ml of fresh Milli-Q water was added to keep the volume constant. The 
withdrawals were measured with UV-vis spectrometer (Shimadzu UV-1800). In order to 
calculate the amount of released sulindac, the absorbance was taken at 286 nm then 
converted to mass (µg) using a calibration curve.  All the release experiments were performed 
in triplicate. 
2.2.4 Grafting of Fluoresceinamine on the particles via reductive amination 
Grafting of the fluoresceinamine was performed according to previously published conditions 
(Freichels et al., 2012). The procedure is described as follows: the UV-cleaved particles (100 
mg, 1 equivalent of aldehyde groups) were suspended in 50 ml of phosphate buffer solution 
(500mM, pH: 7.4) and fluoresceinamine isomer 1 (2 equivalents) was added. After 1 hour of 
stirring, a 10-fold excess sodium cyanaborohydride solution (1.0 M in THF) was added. The 
mixture was left for stirring for 96 hours and then dialyzed against water for 3 days by 
changing water for 4 times per day. Particles were recovered by rotary evaporator and freeze-
drying.  
2.3 Characterisation 
All the particles were analyzed with scanning electron microscopy (SEM, JEOL JSM 840-A) to 
evaluate their morphology. Samples were prepared on SEM stubs and coated with Pt (30 nm). 
Particles average sizes were calculated from SEM images by random sampling of 75-100 
particles with the aid of VistaMetrix software (version 1.33.0). Coefficient of variance (Cv) is 
an indicator of size distribution of the particles. It is calculated from the standard deviation 
(σ) divided by the average diameter size (Dn) that is calculated from the SEM images (Cv 
=(σ/Dn)*100) (Eq.1). Transmission electron microscopy (TEM, PHILIPS M100) operating at an 
accelerating voltage of 100 kV was used to further evaluate the particles size. TEM samples 
were prepared by placing a drop of diluted dispersion of particles on a TEM grid and left for 
air drying. The size distribution of particles in suspension in diluted TFT (before UV) and in 
water (after UV) were estimated by dynamic light scattering (DLS) using a Delsa Nano C 
Beckman Coulter at 25°C. The DLS measurements were performed in triplicate for each 
sample. The intensity of scattered light was detected at 165° to the incident beam and data 
treated by the cumulant analysis. X-ray photoelectron Spectroscopy (XPS) analyses were 
performed on a SSX 100/206 spectrometer (Surface Science Instruments - USA) equipped with 
a monochromatized micro-focused aluminum X-ray source (powered at 20 mA and 10 kV). A 
flood gun set at 6 eV and a Ni grid placed 3 mm above the sample surface were used for 
charge stabilisation. The angle between the surface normal and the axis of the analyser lens 
was 55°; in these conditions, the probed depth was of the order of 5 nm. The molar fractions 
were calculated from the peak areas normalized on the basis of the acquisition parameters 
and sensitivity factors provided by the manufacturer. The calculations exclude hydrogen 
which is not detected by XPS. Carbon and fluorine spectra recorded second time after the 
analysis in order to validate that the sample was not degraded by X-ray source. The data 
analysis was performed with the CasaXPS program (Casa Softwares, Teignmouth, UK).   
3. Results and discussion 
1.1 One-pot sulindac encapsulation by in-situ dispersion polymerisation 
of HEMA 
The one-pot encapsulation of sulindac into cross-linked poly(HEMA) particles has been first 
studied by following a previously reported supercritical CO2 process. Indeed, mild reaction 
conditions (35°C and 300 bar) were reported previously (Parilti et al., 2017) to synthesize well-
defined poly(HEMA) particles by dispersion polymerisation in scCO2. Following such process, 
the monomer, HEMA (10% v/v CO2), the cross-linker, EGDMA (5% v/v monomer), the 
photocleavable stabiliser, PEO45-h-PFDA50 (0.82 g) and the initiator, V-70 (1% w/v monomer) 
were introduced in the high-pressure cell, together with the sulindac in order to perform its 
one-pot encapsulation. Two different concentrations of sulindac 0.1% and 1% with respect to 
monomer (%,wsulindac/wHEMA) have been tested. After polymerization at 35°C under 300 bar 
for at least 18h, the reactor is depressurized and a dry powder is collected. Let us mention 
that thanks to the solubility of the HEMA monomer and residual initiator in scCO2, potential 
traces of unreacted HEMA after reaction would be extracted during venting. However, this 
was not extensively observed since full conversion is expected. Therefore, the collected 
powder can be used as collected from the reactor without requiring further purification 
process. The collected powder is first analysed by scanning and transmission electron 
microscopy (SEM/TEM). The overall characteristics of the obtained particles in presence of 
sulindac are reported in Table 1 and the corresponding SEM and TEM images are reported in 
Figure 1. They are compared to particles prepared in the same conditions but in absence of 
sulindac (Table 1, Entry 1; Figures 1, 1a and 1b). 
Table 1: characteristics of the powder as collected after scCO2 dispersion polymerisation 
 
 
a: amount of sulindac added in the reactor before polymerization 
b:Measurement taken in trifluorotoluene (TFT). 
c: amount of free sulindac in the collected dry powder (wfree sulindac/winitial sulindac  100) 
Entry Initial sulindaca 
(%,wsulindac/wHEMA) 
SEM  
(nm) 
Cv DLS 
(nm) 
Free sulindacc 
(%) 
1 0 348 8 256 b - 
2 0.1 561 6 328b 18.3 
3 1 336 9 280b 1.8 
 Figure 1: SEM image of the poly(HEMA) particles 1) without sulindac, 2) with 0.1% sulindac and 3) with 
1% sulindac; and (1a and 1b) TEM image without sulindac (1b scale bar 100nm).  
 
As evidenced by the SEM image of figure 1.1, the empty cross-linked poly(HEMA) particles 
exhibit a highly uniform spherical shape of small sizes, 348 nm. This was confirmed by TEM 
image (Figure 1-1a and 1b) giving a size of 230 nm. For TEM measurement, the particles were 
suspended in tetrahydrofuran (THF) and a drop was placed on the TEM grid whereas for SEM, 
TFT, a good solvent for the stabiliser on the surface, was used. Therefore, difference between 
SEM size (348 nm) and TEM (230) results from different swelling state during sample 
preparation. As shown on figures 1.2 and 1.3, the addition of sulindac to the reaction medium 
does not affect the particles formation, shape and dispersity. Table 1 also shows that the 
particles size, measured by SEM or DLS, is not significantly modified by the presence of 1% of 
sulindac. Only the particles prepared in presence of 0.1% sulindac are slightly bigger. 
 Figure 2:  Sulindac loaded poly(HEMA) networks dispersed in water before UV (1), dispersed in water 
after UV (2). 
The dry particles collected after depressurization of the reactor are expected to be composed 
of a poly(HEMA) network loaded by the sulindac and coated at their surface by the fluorinated 
stabiliser which prevents their dispersion and swelling in water as illustrated in Figure 2.1.. In 
order to evaluate the amount of free sulindac that is not encapsulated in the particles, the 
dry powder collected from the high-pressure reactor was suspended in water under vigorous 
stirring (app. 750 rpm for 1 hour) to insure their contact with water despite the fluorinated 
corona. By this way, only the sulindac which is adsorbed at the particles surface or that 
remains non-encapsulated in the particles would be able to dissolve in water. After filtration 
on 0.2 µm filter in order to remove the particles, the UV-vis absorptions (286 nm) of the 
aqueous solutions were recorded and converted to mass of sulindac using a previously 
recorded calibration curve (Guerra et al., 2016). Based on these UV-VIS data, the amount of 
free sulindac were found to be 18.3% for 0.1wt% sulindac (Table 1-Entry 2) and 1.8% for 1wt% 
starting sulindac content (Table 1-Entry 3). This shows that especially in the case of 1wt% 
sulindac, very few amount of sulindac remains free at the term of the scCO2 process due to 
the high solubility of sulindac in HEMA and poor solubility in scCO2.  
 
As shown in Figure 2.1, the dry particles collected after depressurization of the reactor are 
cannot be dispersed directly in water due to the hydrophobic external corona formed by the 
fluorinated block (PFDA) of the stabiliser. Before release experiments, the fluorinated block 
of the stabiliser was thus removed thanks to the photocleavable link placed at the junction of 
both blocks.  
For this end, sulindac encapsulated particles were subjected to UV-photolysis (Scheme 2) in 
TFT, i.e. a good solvent for the fluorinated block which does not swell the poly(HEMA) 
network. After 30 minutes or 60 minutes, the irradiation was stopped and the samples were 
washed with fresh TFT to remove the cleaved fluorinated block and dried under vacuum. 
Since polyHEMA does not swell at all in TFT and since sulindac is insoluble in TFT, the release 
of sulindac cannot start during this step. Only the sulindac that would be trapped in the 
fluorinated shell could be lost. In addition, the solid poly(HEMA) network surrounding the 
sulindac might preserve it from UV photodegradation. As it is evidenced from the SEM images 
(Figure 3) despite the aggregation of the particles, their shape was preserved after UV and 
extraction of the fluorinated block (Scheme 2 – step 1). 
 Scheme 2: UV-photolysis of the obtained poly(HEMA) particles were performed in TFT. Photocleavage 
of the stabiliser leads to formation of the o-nitrosobenzaldehyde groups on the particle surface and 
subsequently fluorinated block is extracted. The photo-isomerisation of the stabiliser results in the 
cleavage of the PEO-hv-PFDA stabiliser into first block (PEO) bearing nitrosobenzaldehyde group and 
carboxylic acid group at the end of second block (PFDA). 
 
 
Figure 3: SEM images of the sulindac (0.1% and 1% loaded poly(HEMA) particles after 1 hour UV-
photolysis (scale bar 3µm). 
For each sample, the efficiency of removal of the fluorinated layer from the particles was 
determined by X-ray photoelectron spectroscopy (XPS) by comparing the evolution of the 
total F/C ratios of the particles before and after photolysis of different durations (Table 2).  
Table 2: XPS and DLS analyses of sulindac loaded poly(HEMA) particles for various times of UV-
irradiation. 
 a: in trifluorotoluene (TFT) b: in water. 
Table 2 clearly evidences that the fluorine content of the particles decreases for increasing 
UV-irradiation times. In previous work, Alaimo et al.28 reported on the kinetics of particles 
photolysis using 0.1 mg particle/ml of TFT (LOT-Oriel UV-lamp was used) and fluorine 
extraction in TFT. According to the reported results, after 30 minutes of irradiation 72% of 
fluorine could be extracted. The kinetics of photocleavage reached to a plateau after 30 
minutes and maximum extraction was reached after 6 hours (79% fluorine extraction).  
In our case, the photocleavage time was set to relatively short times (30 minutes and 60 
minutes) in order to prevent degradation of the guest molecule. Moreover, the concentration 
of the particle dispersion for photocleavage was increased to 10 mg/ml, to lower the TFT 
amount. Therefore, direct comparison between these studies cannot be drawn but they are 
roughly giving similar fluorine extraction efficiency.   
In this case, one hour of irradiation leads to the removal of half of the PFDA block from the 
particles surface. After this treatment, the resulting particles become dispersable in water 
(Figure 2- 2) and are able to swell thanks to the strong hydrophilicity of poly(HEMA) (Scheme 
Entry Sulindac 
(%,wsulindac/wHEMA) 
UV-Time 
(mins) 
F/C (tot) 
(XPS) 
     Fluorine 
Extraction (%) 
Particle Size 
  (DLS)a,b 
1 0.1 0 0.89 ----- 328nma 
2 1 0 0.73 ----- 280nma 
3 0.1 30 0.52 41.5 2.1 µmb 
4 0.1 60 0.47 47.1 2.6 µmb 
5 1 30 0.44 36.7 2.7 µmb 
6 1 60 0.35 52.0 3.6 µmb 
2 – step 2). This water swelling was clearly evidenced by DLS. In water, there is a significant 
increase of the particle size of at least one order of magnitude in each case. This shows that 
even if some fluorinated chains remain at the particles surface, the cross-linked poly(HEMA) 
are remarkably able to swell in water (36% of extracted fluorine leads already to a size 
increase from 271 nm to 2.7 µm). This shows the relatively low impact of the remaining 
fluorine chains on the particles swelling in water more importantly it does not prevent their 
water dispersion.  
3.2 Determination of the particles loading and release behaviour. 
Firstly, the barrier effect of the fluorinated corona of the particles towards the diffusion of 
sulindac to water was investigated. The particles (15 mg) loaded with 1% sulindac (Table 2-
Entries 2, 5 and 6) before photolysis, after 30 minutes or 1 hour exposure to UV light, have 
been dispersed in water and stirred for 24 hours. The amount of released sulindac was then 
determined by UV-vis measurements. Figure 4 clearly shows that the particles before UV 
treatment limit the release of sulindac to 2.4 microgram, i.e. 1.5%). 
 
Figure 4: UV-Vis spectra of released sulindac in water from 1% sulindac loaded particles (Table 2-Entry 
2) Blue: without UV treatment (Table 2-Entry 2); Red: after 30 minutes of UV treatment (Table 2-Entry 
5); Green after 1 hour of UV treatment (Table 2- Entry 6). 
After photolysis and partial removal of the fluorinated corona, the amount of released 
sulindac increased to approximately 10 micrograms for both particles subjected to different 
UV-irradiation times (30 minutes and 1 hour). This clearly shows that the fluorinated corona 
acts as a barrier towards the sulindac diffusion however this barrier effect is clearly decreased 
already after short time of UV irradiation (30 min).  
Then, the release profile in water and in sink conditions of the hydrogel particles synthesized 
by loading the scCO2 reactor with 1% sulindac and exposed to 1 hour UV for removal of the 
fluorinated block was monitored during 37 days (Figure 5).  
 
Figure 5: Sulindac cumulative release profile from the particles synthesized by loading the reactor 
with 1wt% sulindac.  
Figure 5 shows the cumulative release of sulindac and evidences a Burst effect after 24h, 
followed by a quite linear release between 1 and 10 days that then levels until 37 days when 
a complete release is reached. Betweeen 10 days and 37 days, the sulindac release stops 
because the particles become empty. From the amount of released sulindac measured after 
37 days (i.e. 8.6 mg), a particle loading corresponding to 8.6mg per gram of particles can be 
calculated. Such loading corresponds to a drug encapsulation efficiency of 86% for the entire 
developed scCO2 and photocleavage process. It is important to mention that the released 
sulindac possesses the same spectroscopic signature as the initial sulindac engaged in the 
encapsulation process as confirmed by UV-VIS spectrum. These results show that at least 86% 
of the initial sulindac remains unaltered by the whole encapsulation process that includes the 
polymerization in scCO2 and the photocleavage in TFT. Since we have determined above that 
2% of this sulindac is not encapsulated at the end of the scCO2 polymerization, it means that 
only 12% of the intial sulindac is altered and/or lost during the encapsulation process.  
 
Figure 6: Sulindac release profile per day from the particles loaded with 1wt% sulindac. 
Figure 6 shows the daily release for the first 9 days. In the Burst effect observed in the first 
24h, 25% of the loaded sulindac is released. Then, a quite linear controlled release of about 
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500 µg/g per day is observed over the whole period of 8 days. After 9 days, 88 % of the total 
load is thus released.  
As recently reported by Scavo et al., 2015, encapsulation of the NSAIDs such as sulindac in 
drug delivery systems is expected to increase the therapeutic effect along with decreasing the 
side effect for long-term administration. Our encapsulation process, allowing a constant 
release over 9 days might be quite promising espacially for locoregional treatment, e.g. 
placing the particles during a surgery, to insure a sustained release of the sulindac during a 
few days. Due to this, we believe that encapsulation of a chemopreventive drug such as 
sulindac in a facile method is very interesting from the production and medical point of view.  
3.3 Grafting on the particle surfaces 
As discussed above, selecting a stabiliser (PEO-hν-PFDA) that exhibit a photocleavable o-
nitrobenzyl group at the junction of the blocks of the copolymer allows the removal at least 
partially of the fluorinated block modifying the release kinetics of sulindac. Looking closer to 
the photoreaction (scheme 2), the light-induced cleavage of o-nitrobenzyl group generates a 
nitrosobenzaldehyde group at the end of the PEO segment entangled in the poly(HEMA) 
particles. These aldehyde groups located at the external periphery of the particles could be 
useful to further functionalisation of the particle surfaces. For instance, different probes for 
imaging or targeting could be grafted thanks to the aldehyde reactivity.  
In the present study, the aldehyde groups have been used for grafting a fluorescent probe, 
i.e. the fluoresceinamine on the particle surface by using reductive amination.  Reported 
conditions for reductive amination reaction by Freichels et al. (Freichels et al., 2012) have 
been followed as described in details in the experimental part.  Extensive washing (i.e 3 days) 
by dialysis had been carefully performed after grafting. In order to eliminate the excess 
amount of fluoresceinamine that is not grafted onto the particles  
 
Figure 7: The fluorescence microscopy images of the particles tagged with fluorescent probe.  
 
While before reaction with fluoresceinamine, the particles exhibit no fluorescence (not 
shown), they clearly emit the typical green light of the grafted fluorescein as it can be seen 
from the fluorescence microscope image (Figure 7). This confirms that the developed process 
is able not only to provide particles allowing a sustained release of the encapsulated drug but 
also that the particles can be labelled with fluorescent probe by taking profit of the reactive 
groups generated by the photocleavage.  
4. Conclusions 
 
One-pot encapsulation of sulindac in poly(HEMA) networks was successfully performed in 
supercritical carbon dioxide. The poly(HEMA) networks with or without sulindac were both 
produced with monodispersity and well-defined morphology and small size (271nm). The 
scCO2 can be removed from the reaction medium by simple depressurisation which eliminates 
the reaction work-up step for purification and/or drying and leads after venting to the loaded 
particles as a dry powder with only 1.8% of remaining free sulindac for a targeted loading of 
1%.  
In addition, by using a photocleavable stabiliser, part of the fluorinated block can be extracted 
from the surface allowing the particles to be dispersed and swollen in aqueous media. Already 
after 30min. of UV-photolysis, extensive swelling of the particles is observed when placed in 
water leading to swollen microgels of about 2.7 µm with an encapsulation efficiency of 86%. 
Interestingly, after photocleavage, the generated aldehyde functions on the particle surface 
enables to perform further chemical functionalization with amine derivatives. As a proof of 
concept, a fluorescent dye was grafted by using fluoresceinamine leading to particles that can 
be detected by fluorescence microscope. This reductive amination step performed in aqueous 
media could be applied to a variety of amino-functional (macro)molecules of use for imaging 
or targeting. The described process allows thus to produce in few steps, well-defined 
multifunctional microgels. Thanks to mild reaction conditions  (i.e 35°C) and the non-toxic, 
inert and environmentally friendly polymerisation medium (scCO2), this process could be 
extended to heat or solvent-sensitive API and constitutes a promising process for advanced 
formulations.  
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